Back to top
more

Xencor (XNCR)

(Delayed Data from NSDQ)

$19.98 USD

19.98
375,500

+0.75 (3.90%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $19.98 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for XNCR

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Xencor, Inc. [XNCR]

Reports for Purchase

Showing records 201 - 216 ( 216 total )

Company: Xencor, Inc.

Industry: Medical - Drugs

Record: 201

10/28/2014

Company Report

Pages: 5

Regains Full Rights to XmAb5871, Refocuses Development from RA to Rare Autoimmune Disorder;

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Company: Xencor, Inc.

Industry: Medical - Drugs

Record: 202

10/12/2014

Daily Note

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of Oct 13

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Xencor, Inc.

Industry: Medical - Drugs

Record: 203

09/29/2014

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of Sept 29

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Xencor, Inc.

Industry: Medical - Drugs

Record: 204

08/13/2014

Industry Report

Pages: 15

LIFE SCIENCES AND HEALTH CARE-2014 LSMAC Day 1

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 50.00

Research Provided by a Third Party

Company: Xencor, Inc.

Industry: Medical - Drugs

Record: 205

08/13/2014

Daily Note

Pages: 15

2014 LSMAC Day 1

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 50.00

Research Provided by a Third Party

Company: Xencor, Inc.

Industry: Medical - Drugs

Record: 206

08/01/2014

Industry Report

Pages: 6

The Week Ahead in Life Sciences - Upcoming Events for the Week of August 4

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Xencor, Inc.

Industry: Medical - Drugs

Record: 207

07/31/2014

Company Report

Pages: 5

Q2 EPS; Data From 7195 and 5871 Coming Up by YE:14, Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Company: Xencor, Inc.

Industry: Medical - Drugs

Record: 208

07/27/2014

Industry Report

Pages: 6

LIFE SCIENCES AND HEALTH CARE

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Xencor, Inc.

Industry: Medical - Drugs

Record: 209

05/28/2014

Daily Note

Pages: 5

Transitioning Coverage, Phase I Trial of XmAb7195 Begins, Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Company: Xencor, Inc.

Industry: Medical - Drugs

Record: 210

05/28/2014

Daily Note

Pages: 5

Transitioning Coverage, Phase I Trial of XmAb7195 Begins, Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Company: Xencor, Inc.

Industry: Medical - Drugs

Record: 211

04/09/2014

Daily Note

Pages: 11

Bispecifics Emerge: Preclinical Data with a CD38 Bispecific Demonstrate Anti-Tumor Activity in Multiple Myeloma - Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: MARAI C

Price: 25.00

Research Provided by a Third Party

Company: Xencor, Inc.

Industry: Medical - Drugs

Record: 212

04/09/2014

Daily Note

Pages: 11

Bispecifics Emerge: Preclinical Data with a CD38 Bispecific Demonstrate Anti-Tumor Activity in Multiple Myeloma - Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: MARAI C

Price: 25.00

Research Provided by a Third Party

Company: Xencor, Inc.

Industry: Medical - Drugs

Record: 213

03/25/2014

Company Report

Pages: 10

Q4 Update - XmAb7195 Data YE:14

Provider: WEDBUSH SECURITIES INC.

Analyst: MARAI C

Price: 25.00

Research Provided by a Third Party

Company: Xencor, Inc.

Industry: Medical - Drugs

Record: 214

03/03/2014

Daily Note

Pages: 9

Attractive Bispecific Candidates Masked by ''7195 - XNCR Overlooked and Undervalued Relative to Comps - Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: MARAI C

Price: 25.00

Research Provided by a Third Party

Company: Xencor, Inc.

Industry: Medical - Drugs

Record: 215

03/03/2014

Daily Note

Pages: 9

Attractive Bispecific Candidates Masked by ''7195

Provider: WEDBUSH SECURITIES INC.

Analyst: MARAI C

Price: 25.00

Research Provided by a Third Party

Company: Xencor, Inc.

Industry: Medical - Drugs

Record: 216

12/31/2013

Company Report

Pages: 35

Initiating with an OUTPERFORM Rating and $18 Price Target: Rationally Fc-Engineering a Novel Portfolio of Antibodies Targeting Unmet Medical Needs

Provider: WEDBUSH SECURITIES INC.

Analyst: LYON C

Price: 75.00

Research Provided by a Third Party